Publikasi Scopus 2023 per tanggal 31 Juli 2023 (506 artikel)

Nelwan E.J.; Shakinah S.; Pasaribu A.
14527452900; 57428569400; 57428543800
Association of G6PD status and haemolytic anaemia in patients receiving anti-malarial agents: a systematic review and meta-analysis
2023
Malaria Journal
22
1
77
0
Division of Tropical and Infectious Disease, Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Division of Tropical and Infectious Disease, Internal Medicine Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Nelwan E.J., Division of Tropical and Infectious Disease, Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Division of Tropical and Infectious Disease, Internal Medicine Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Shakinah S., Division of Tropical and Infectious Disease, Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Division of Tropical and Infectious Disease, Internal Medicine Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Pasaribu A., Division of Tropical and Infectious Disease, Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Division of Tropical and Infectious Disease, Internal Medicine Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Background: Some anti-malarial drugs often cause haemolytic anaemia in glucose-6-phosphate-dehydrogenase deficiency (G6PDd) patients. This study aims to analyse the association of G6PDd and anaemia in malaria patients receiving anti-malarial drugs. Methods: A literature search was performed in major database portals. All studies searched using keywords with Medical Subject Headings (MeSH) were included, without date or language restriction. Pooled mean difference of haemoglobin and risk ratio of anaemia were analysed using RevMan. Results: Sixteen studies comprising 3474 malaria patients that included 398 (11.5%) with G6PDd were found. Mean difference of haemoglobin in G6PDd/G6PD normal (G6PDn) patients was − 0.16 g/dL (95% CI − 0.48, 0.15; I2 5%, p = 0.39), regardless of the type of malaria and dose of drugs. In particular with primaquine (PQ), mean difference of haemoglobin in G6PDd/G6PDn patients with dose < 0.5 mg/kg/day was − 0.04 (95% CI − 0.35, 0.27; I2 0%, p = 0.69). The risk ratio of developing anaemia in G6PDd patients was 1.02 (95% CI 0.75, 1.38; I2 0%, p = 0.79). Conclusion: Single or daily standard doses of PQ (0.25 mg/kg/day) and weekly PQ (0.75 mg/kg/week) did not increase the risk of anaemia in G6PDd patients. © 2023, The Author(s).
Antimalarial; G6PD deficiency; Malaria falciparum; Malaria vivax; Primaquine
Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Primaquine; amodiaquine; antimalarial agent; artemisinin; atovaquone; benflumetol; clindamycin; doxycycline; glucose 6 phosphate dehydrogenase; hemoglobin; primaquine; proguanil; pyrimethamine; tafenoquine; antimalarial agent; chrysarobin; glucose 6 phosphate dehydrogenase; primaquine; disease association; dose response; glucose 6 phosphate dehydrogenase deficiency; hemolytic anemia; human; malaria; meta analysis; Review; risk assessment; risk factor; single drug dose; systematic review; glucose 6 phosphate dehydrogenase deficiency
Universitas Prima Indonesia, UNPRI; Universitas Indonesia, UI, (NK-1295-3904/UN2.RST/HKP.05.00/2020)
Funding text 1: The authors would like to thank Universitas Indonesia for funding this research through PUTI Grant with contract number NK-1295-3904/UN2.RST/HKP.05.00/2020. ; Funding text 2: This study was funded by the PUTI Universitas Indonesia grant. The funding bodies do not have roles in this review.
BioMed Central Ltd
14752875
36872344
Review
Q1
1307
2662